A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.

@article{Montaner1997APS,
  title={A pilot study of hydroxyurea among patients with advanced human immunodeficiency virus (HIV) disease receiving chronic didanosine therapy: Canadian HIV trials network protocol 080.},
  author={Julio S. G. Montaner and Carlos A Zala and Brian Conway and Janet M. Raboud and P. Patenaude and Sandra Rae and M. V. O'shaughnessy and Martin T. Schechter},
  journal={The Journal of infectious diseases},
  year={1997},
  volume={175 4},
  pages={801-6}
}
To assess the in vivo short-term antiretroviral effect of hydroxyurea in human immunodeficiency virus (HIV)-infected persons chronically treated with didanosine (ddI), 26 patients with CD4 cell counts between 100 and 350 were enrolled in a 12-week, open-label pilot study and randomly assigned to receive 500 or 1000 mg/day hydroxyurea. Clinical status, laboratory toxicities, CD4 lymphocyte count, and HIV RNA plasma virus load were assessed weekly. Median declines from baseline of 0.02 and 0.63… CONTINUE READING

Citations

Publications citing this paper.
Showing 1-10 of 13 extracted citations

Combination Therapy of AIDS

Milestones in Drug Therapy MDT • 2004

Antiviral Chemotherapy 5

Advances in Experimental Medicine and Biology • 1999

Similar Papers

Loading similar papers…